Patent: 6,033,665
✉ Email this page to a colleague
Summary for Patent: 6,033,665
Title: | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
Abstract: | The invention is directed to compositions and methods for modulating the adhesion of leukocytes to brain endothelial cells. More specifically, the present invention relates to the use of reagents to inhibit the binding of VLA-4 leukocyte cell surface receptors to brain endothelial adhesion molecules. Also provided are compositions and methods for treating brain inflammation. A method of inducing brain inflammation as well as an assay for testing anti-inflammatory agents is also provided. |
Inventor(s): | Yednock; Theodore A. (Fairfax, CA) |
Assignee: | Elan Pharmaceuticals, Inc. (South San Francisco, CA) |
Application Number: | 08/457,847 |
Patent Claims: | see list of patent claims |
Details for Patent 6,033,665
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | 11/23/2004 | ⤷ Try a Trial | 2017-03-07 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 6,033,665
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 9105038 | ⤷ Try a Trial |
United States of America | 5260210 | ⤷ Try a Trial |
Japan | H05503920 | ⤷ Try a Trial |
Japan | 3308526 | ⤷ Try a Trial |
Japan | 2002284700 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |